Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with platinum-doublet chemotherapy. All participants will be given with albumin-bound paclitaxel, lenvatinib and pembrolizumab.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06028633
Study type Interventional
Source Peking University First Hospital
Contact Shikai Wu
Phone (86)18910715326
Email skywu4329@sina.com
Status Not yet recruiting
Phase Phase 2
Start date October 2023
Completion date October 2026

See also
  Status Clinical Trial Phase
Completed NCT04959981 - A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC Phase 1
Not yet recruiting NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) Phase 2
Not yet recruiting NCT06416410 - JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Phase 3
Withdrawn NCT03190239 - Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients Phase 2
Withdrawn NCT03792503 - Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen Phase 4
Recruiting NCT05648071 - First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial Phase 3
Recruiting NCT04416035 - A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC Phase 3